← Back to home

REVERSING ROCURONIUM-INDUCED NEUROMUSCULAR BLOCKADE IN PATIENTS UNDERGOING GENERAL ANESTHESIA SURGERY

Clinical trials for REVERSING ROCURONIUM-INDUCED NEUROMUSCULAR BLOCKADE IN PATIENTS UNDERGOING GENERAL ANESTHESIA SURGERY explained in plain language.

Never miss a new study

Get alerted when new REVERSING ROCURONIUM-INDUCED NEUROMUSCULAR BLOCKADE IN PATIENTS UNDERGOING GENERAL ANESTHESIA SURGERY trials appear

Sign up with your email to follow new studies for REVERSING ROCURONIUM-INDUCED NEUROMUSCULAR BLOCKADE IN PATIENTS UNDERGOING GENERAL ANESTHESIA SURGERY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New drug aims to speed up recovery from anesthesia muscle relaxants

Symptom relief Not yet recruiting

This Phase 2 trial tests amogammadex sodium, a drug designed to reverse the effects of common muscle relaxants (rocuronium or vecuronium) used during surgery. About 64 adults having elective surgery will receive the drug at the end of their procedure. Researchers will measure how…

Matched conditions: REVERSING ROCURONIUM-INDUCED NEUROMUSCULAR BLOCKADE IN PATIENTS UNDERGOING GENERAL ANESTHESIA SURGERY

Phase: PHASE2 • Sponsor: Amckaus PTY LTD. • Aim: Symptom relief

Last updated Jun 27, 2026 12:35 UTC

REVERSING ROCURONIUM-INDUCED NEUROMUSCULAR BLOCKADE IN PATIENTS UNDERGOING GENERAL ANESTHESIA SURGERY

Get alerted when new REVERSING ROCURONIUM-INDUCED NEUROMUSCULAR BLOCKADE IN PATIENTS UNDERGOING GENERAL ANESTHESIA SURGERY trials appear

New drug aims to speed up recovery from anesthesia muscle relaxants